Aminologics Co.,Ltd. (KOSDAQ:074430)
South Korea · Delayed Price · Currency is KRW 1,210.00
-8.00 (-0.66%)
At close: Jun 10, 2026
Aminologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 22,676 | 22,020 | 16,790 | 20,887 | 27,337 | 22,849 |
Other Revenue | - | - | - | - | -0 | -0 |
| 22,676 | 22,020 | 16,790 | 20,887 | 27,337 | 22,849 | |
Revenue Growth (YoY) | 36.76% | 31.15% | -19.61% | -23.60% | 19.64% | 29.45% |
Cost of Revenue | 12,470 | 12,188 | 13,406 | 13,153 | 14,547 | 13,721 |
Gross Profit | 10,206 | 9,832 | 3,384 | 7,734 | 12,790 | 9,128 |
Selling, General & Admin | 5,809 | 5,611 | 4,966 | 4,527 | 5,179 | 4,255 |
Research & Development | 207.13 | 139.57 | 112.54 | 1,307 | 215.51 | 474.13 |
Amortization of Goodwill & Intangibles | 13.8 | 16.68 | 19.64 | 19.7 | 19.26 | 16.31 |
Other Operating Expenses | -6.13 | -1.94 | -6.05 | -8.14 | 9.56 | 16.06 |
Operating Expenses | 6,494 | 6,238 | 5,537 | 6,272 | 5,881 | 5,174 |
Operating Income | 3,712 | 3,594 | -2,153 | 1,462 | 6,908 | 3,953 |
Interest Expense | -1,459 | -984.46 | -83.42 | -57.08 | -40.01 | -30.92 |
Interest & Investment Income | 1,338 | 1,287 | 1,175 | 929.76 | 525.7 | 198.06 |
Currency Exchange Gain (Loss) | 955 | 125.62 | 879.8 | -75.28 | 397.24 | 465.53 |
Other Non Operating Income (Expenses) | -1,000 | -799.84 | 42.61 | 133.25 | 105.51 | -8.26 |
EBT Excluding Unusual Items | 3,545 | 3,222 | -138.97 | 2,393 | 7,897 | 4,578 |
Gain (Loss) on Sale of Investments | -167.51 | 1,351 | 11.98 | -101.82 | -659.69 | 658.99 |
Gain (Loss) on Sale of Assets | - | - | 8.41 | - | - | - |
Asset Writedown | -1,058 | -1,058 | -986 | - | -13,518 | -1,533 |
Pretax Income | 2,319 | 3,515 | -1,105 | 2,291 | -6,281 | 3,704 |
Income Tax Expense | 60.53 | -6.54 | 515.44 | -145.31 | 1,001 | -1,656 |
Net Income | 2,259 | 3,522 | -1,620 | 2,436 | -7,282 | 5,360 |
Net Income to Common | 2,259 | 3,522 | -1,620 | 2,436 | -7,282 | 5,360 |
Net Income Growth | - | - | - | - | - | 150.46% |
Shares Outstanding (Basic) | 88 | 88 | 90 | 88 | 88 | 88 |
Shares Outstanding (Diluted) | 88 | 88 | 90 | 88 | 88 | 88 |
Shares Change (YoY) | -1.26% | -2.42% | 2.48% | - | - | - |
EPS (Basic) | 25.53 | 40.10 | -18.00 | 27.74 | -82.91 | 61.03 |
EPS (Diluted) | 25.53 | 40.10 | -18.00 | 27.74 | -82.91 | 61.03 |
EPS Growth | - | - | - | - | - | 150.46% |
Free Cash Flow | 7,552 | 2,495 | 6,955 | -373.95 | 4,736 | 419.81 |
Free Cash Flow Per Share | 85.34 | 28.41 | 77.27 | -4.26 | 53.92 | 4.78 |
Gross Margin | 45.01% | 44.65% | 20.16% | 37.03% | 46.79% | 39.95% |
Operating Margin | 16.37% | 16.32% | -12.82% | 7.00% | 25.27% | 17.30% |
Profit Margin | 9.96% | 15.99% | -9.65% | 11.66% | -26.64% | 23.46% |
Free Cash Flow Margin | 33.30% | 11.33% | 41.42% | -1.79% | 17.32% | 1.84% |
EBITDA | 4,196 | 4,083 | -1,688 | 1,908 | 7,259 | 4,232 |
EBITDA Margin | 18.50% | 18.54% | -10.05% | 9.14% | 26.55% | 18.52% |
D&A For EBITDA | 484.02 | 489.49 | 465.43 | 446.15 | 350.84 | 278.81 |
EBIT | 3,712 | 3,594 | -2,153 | 1,462 | 6,908 | 3,953 |
EBIT Margin | 16.37% | 16.32% | -12.82% | 7.00% | 25.27% | 17.30% |
Advertising Expenses | - | 41.47 | 132.5 | 91.26 | 26.12 | 63.09 |